Patents - stay tuned to the technology

Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Hydroxy, bonded directly to carbon, or ether oxygen attached directly or indirectly to the acyclic carbon or chain by acyclic nonionic bonding with no amino nitrogen between the hydroxy or ether oxygen and the aryl ring or ring system (H of -OH may be replaced by a substituted or unsubstituted ammonium ion or a Group IA or IIA light metal)

Subclass of:

564 - Organic compounds -- part of the class 532-570 series

564000000 - ORGANIC COMPOUNDS (CLASS 532, SUBCLASS 1)

564001000 - AMINO NITROGEN CONTAINING (E.G., UREA, SULFONAMIDES, NITROSAMINES, OXYAMINES, ETC., AND SALTS THEREOF)

564305000 - Benzene ring containing

564336000 - Amino nitrogen attached to aryl ring or ring system by an acyclic carbon or chain

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
564355000 Hydroxy, bonded directly to carbon, or ether oxygen attached directly or indirectly to the acyclic carbon or chain by acyclic nonionic bonding with no amino nitrogen between the hydroxy or ether oxygen and the aryl ring or ring system (H of -OH may be replaced by a substituted or unsubstituted ammonium ion or a Group IA or IIA light metal) 22
20080221356Processes for the synthesis of O-desmethylvenlafaxine - The present invention describes processes for the preparation of O-desmethylvenlafaxine and tridesmethylvenlafaxine, which may be used as an intermediate in preparing O-desmethylvenlafaxine.09-11-2008
20080275272AMINE COMPOUNDS AND INHIBITING NEUROTRANSMITTER REUPTAKE - The invention relates to amine compounds as well as methods and materials involved in modulating neurotransmitter reuptake. Specifically, the invention provides amine compounds, methods for synthesizing amine compounds, and methods for inhibiting neurotransmitter reuptake.11-06-2008
20090018365Methods for Preparing O-Desmethylvenlafaxine - The present invention provides an efficient method of making O-desmethyl-venlafaxine.01-15-2009
20090069601Processes for the synthesis of O-desmethylvenlafaxine - The present invention describes processes for the preparation of O-desmethylvenlafaxine and tridesmethylvenlafaxine, which may be used as an intermediate in preparing O-desmethylvenlafaxine.03-12-2009
20090292142Substantially pure O-desmethylvenlafaxine and processes for preparing it - Methods for preparing substantially pure O-desmethylvenlafaxine are described.11-26-2009
20100099916Process for the Preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol - The present invention relates to a process for the preparation of (1R,2R)-04-22-2010
20120078016Methods of Synthesizing 2-Substituted-1,4-Benzenediamine - Disclosed is a method of making a 2-substituted-1,4-benzenediamine by nucleophilic aromatic substitution.03-29-2012
20120108848PROCESS FOR RESOLUTION OF 1-(3-HYDROXYPHENYL)-2-METHYLAMINO ETHANOL - Resolution of the title compound to its active isomer (R)-1-(3-hydroxyphenyl)-2-methylamino ethanol with (R)-naproxen as a resolving agent.05-03-2012
564356000 Preparing directly by reduction, other than by reductive amination 7
20090137846Processes for the synthesis of O-Desmethylvenlafaxine - The present invention describes processes for the preparation of O-desmethylvenlafaxine and tridesmethylvenlafaxine, which may be used as an intermediate in preparing O-desmethylvenlafaxine.05-28-2009
20100286447PROCESS FOR PRODUCING 1-[2-(DIMETHYLAMINO)-1-(4-PHENOL)ETHYL]CYCLOHEXANOL - The present invention relates to an improved, process for large scale production of 1-[2-(dimethylamino)-1-(4-phenol)ethyl]cyclohexanol (O-desmethylvenlafaxine) or its pharmaceutically acceptable salts with increased yield and minimal impurities.11-11-2010
20110152574Novel diamino-alcohol compounds and processes for their manufacture - A new class of compounds, namely diamino alcohols, is described, along with a process for their production and their use as dispersing additives for coating formulations.06-23-2011
20140094625Process - The present invention relates to improved processes for the production of 2-amino-2-[2-(4-C04-03-2014
20140235895PREPARATION OF FINGOLIMOD AND ITS SALTS - The present application provide processes for the preparation of fingolimod and its pharmaceutically acceptable salts, process for the purification of fingolimod hydrochloride and process for the preparation of amorphous fingolimod hydrochloride.08-21-2014
564357000 By direct hydrogenation 2
20130123539METHODS FOR PREPARING RITODRINE HYDROCHLORIDE - Methods for preparing Ritodrine hydrochloride are provided. Also provided is non-hygroscopic, crystalline, polymorphic Ritodrine hydrochloride of Form I.05-16-2013
564358000 Group VIII noble metal containing catalyst utilized 1
20100152490Process Of Racemisation Of Optically Active Alpha Aminoacetals - The invention relates to a process for preparing α-aminoacetals substantially in racemic form, comprising a step of oxidizing optically enriched α-aminoacetals to the corresponding oximes, in the presence of a catalyst, and a step of reducing the oximes thus obtained.06-17-2010
564359000 Preparing directly by hydrolysis 1
20090312578PREPARATION OF (2R,3R)-3-(3-METHOXYPHENYL)-N,N,2-TRIMETHYLPENTANAMINE - The present invention relates to an improved process for the preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine which is an intermediate for the preparation of the analgesic tapentadol.12-17-2009
564360000 Additional hydroxy, bonded directly to carbon, or ether oxygen attached directly or indirectly to the acyclic carbon or chain by acyclic nonionic bonding with no amino nitrogen between the additional hydroxy or ether oxygen and the aryl ring or ring system (H of -OH may be replaced by a substituted or unsubstitited ammonium ion or a Group IA or IIA light metal) 5
20090240082Processes for Preparing Venlafaxine and Venlafaxine Hydrochloride of Form I - A process for preparing venlafaxine in a high yield as well as processes for producing venlafaxine hydrochloride of form I having a very hight polymorphic purity are described.09-24-2009
20100191015PROCESS FOR THE PREPARATION OF O-DESMETHYLVENLAFAXINE SUCCINATE POLYMORPHIC FORMS - The present invention relates to process for the preparation of novel crystalline Desmethylvenlafaxine succinate polymorphic Forms-A, B. The present invention also relates to novel processes for the preparation of 0-Desmethylvenlafaxine succinate polymorphic Forms-(I), (II), (III) and amorphous.07-29-2010
20130281739FINGOLIMOD POLYMORPHS AND THEIR PROCESSES - The present invention provides crystalline polymorphic forms of Fingolimod HCl (I) and processes for preparation thereof.10-24-2013
20140066657DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST - S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage03-06-2014
20150344409PROCESS FOR THE PREPARATION OF FINGOLIMOD AND ITS SALTS - The present invention provides process for preparation of Fingolimod hydrochloride (I).12-03-2015
564363000 Beta hydroxy phenethylamines (i.e., hydroxy and the benzene ring are bonded directly to the same carbon of the chain which consists of two carbons; H of -OH may be replaced by a substituted or unsubstituted ammonium ion or a Group IA or IIA light metal) 1
20090112025CATALYTIC HYDROGENATION PROCESS AND NOVEL CATALYST FOR IT - The present invention provides a novel hydrogenation catalyst, process of preparing the catalyst and process for the preparation of optically active L-norephedrine, [(1R,2S)-2-amino-1-phenyl-1-propanol] by a catalytic hydrogenation process, said catalyst comprising of finely divided nickel metal containing a metal from group III A of the periodic table as an activator and a metal from group VI B or VIII as promoter,04-30-2009
Website © 2025 Advameg, Inc.